根据生活方式风险分层的阿司匹林使用与结直肠癌发病率
该前瞻性队列研究纳入护士健康研究(1980-2018)107655名女性与卫生专业人员随访研究(1986-2018)43698名男性,评估阿司匹林使用与不同生活方式风险评分下结直肠癌风险的关系。定期使用阿司匹林者10年累积结直肠癌发病率为1.98%,未使用者为2.95%,绝对风险降低0.97%,且生活方式越不健康者绝对风险降低越大(P<.001)。
要点
- 定期使用阿司匹林者10年结直肠癌累积发病率为1.98%,未使用者为2.95%,绝对风险降低0.97%。
- 生活方式评分0-1分者阿司匹林10年绝对风险降低1.28%,评分4-5分者仅降低0.11%。
- 阿司匹林10年需治疗人数:评分0-1分为78,评分2为164,评分3为154,评分4-5为909。
核心结论
- 在该队列研究中,阿司匹林使用与生活方式较不健康个体中结直肠癌风险的更大绝对降低相关。
- 研究结果提示,生活方式风险因素可能有助于识别在阿司匹林癌症预防中具有更有利风险-获益特征的个体。
研究设计与样本
- 前瞻性队列研究,纳入护士健康研究(1980-2018)中63957名女性和卫生专业人员随访研究(1986-2018)中43698名男性,共107655名参与者,基线平均(SD)年龄49.4(9.0)岁。
- 数据分析于2021年10月1日至2023年5月22日进行。
- 健康生活方式评分基于体重指数、酒精摄入、体力活动、饮食和吸烟计算,评分范围0至5分(分值越高对应越健康的生活方式)。
- 定期使用阿司匹林定义为每周2片及以上标准片剂(325 mg)。
主要发现
- 随访3 038 215人年期间,共记录2544例新发结直肠癌病例。
- 定期使用阿司匹林者10年累积结直肠癌发病率为1.98%(95% CI,1.44%-2.51%),未使用者为2.95%(95% CI,2.31%-3.58%),绝对风险降低0.97%。
- 阿司匹林使用相关的绝对风险降低在不健康生活方式评分者中最大,并随生活方式评分越健康而逐渐减小(加性交互作用P<.001)。
- 生活方式评分0-1分(最不健康)者10年绝对风险降低为1.28%,评分4-5分(最健康)者为0.11%。
- 阿司匹林10年需治疗人数:评分0-1分者为78,评分2者为164,评分3者为154,评分4-5者为909。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Aspirin reduces the risk of colorectal cancer (CRC). Identifying individuals more likely to benefit from regular aspirin use for CRC prevention is a high priority. OBJECTIVE: To assess whether aspirin use is associated with the risk of CRC across different lifestyle risk factors. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study among women in the Nurses' Health Study (1980-2018) and men in the Health Professionals Follow-Up Study (1986-2018) was conducted. Data analysis was performed from October 1, 2021, to May 22, 2023. EXPOSURES: A healthy lifestyle score was calculated based on body mass index, alcohol intake, physical activity, diet, and smoking with scores ranging from 0 to 5 (higher values corresponding to a healthier lifestyle). Regular aspirin use was defined as 2 or more standard tablets (325 mg) per week. MAIN OUTCOME AND MEASURES: Outcomes included multivariable-adjusted 10-year cumulative incidence of CRC, absolute risk reduction (ARR), and number needed to treat associated with regular aspirin use by lifestyle score and multivariable-adjusted hazard ratios for incident CRC across lifestyle scores. RESULTS: The mean (SD) baseline age of the 107 655 study participants (63 957 women from the Nurses' Health Study and 43 698 men from the Health Professionals Follow-Up Study) was 49.4 (9.0) years. During 3 038 215 person-years of follow-up, 2544 incident cases of CRC were documented. The 10-year cumulative CRC incidence was 1.98% (95% CI, 1.44%-2.51%) among participants who regularly used aspirin compared with 2.95% (95% CI, 2.31%-3.58%) among those who did not use aspirin, corresponding to an ARR of 0.97%. The ARR associated with aspirin use was greatest among those with the unhealthiest lifestyle scores and progressively decreased with healthier lifestyle scores (P < .001 for additive interaction). The 10-year ARR for lifestyle scores 0 to 1 (unhealthiest) was 1.28%. In contrast, the 10-year ARR for lifestyle scores 4 to 5 (healthiest) was 0.11%. The 10-year number needed to treat with aspirin was 78 for participants with lifestyle scores 0 to 1, 164 for score 2, 154 for score 3, and 909 for scores 4 to 5. Among the components of the healthy lifestyle score, the greatest differences in ARR associated with aspirin use were observed for body mass index and smoking. CONCLUSIONS AND RELEVANCE: In this cohort study, aspirin use was associated with a greater absolute reduction in risk of CRC among individuals with less healthy lifestyles. The findings of the study suggest that lifestyle risk factors may be useful to identify individuals who may have a more favorable risk-benefit profile for cancer prevention with aspirin.
引用
- Sikavi DR, Wang K, Ma W, et al. Aspirin Use and Incidence of Colorectal Cancer According to Lifestyle Risk. JAMA Oncol. 2024. PMID: 39088221. doi:10.1001/jamaoncol.2024.2503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。